> An NDA from Bayer and Onyx Pharmaceuticals for the kidney cancer drug Sorafenib has been given priority review status by the FDA. The status should lead to a decision on the drug within six months. Story
> BioSante Pharmaceuticals of Lincolnshire, Illinois, has signed a licensing deal with an undisclosed company that it said will be worth up to $10 million. Report
> GTx said it will implement FDA recommendations in the design of its Phase III trial of its experimental prostate cancer therapy. Release
> Teva Pharmaceutical said the FDA has granted final approval for its ANDA for Leflunomide Tablets, a generic treatment for rheumatoid arthritis. Release
And Finally... M.D. Anderson is resuming a study to see if the Cox-2 inhibitor Celebrex can prevent lung damage. Researchers say they'll be on the alert for any cardiovascular risks. Article